share_log

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Benzinga ·  Nov 14 07:07  · Ratings

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $15 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment